Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer
Completed · Phase 2
Conditions studied: Thyroid Neoplasms
In brief
This is a Phase 2 study being conducted at multiple centers in the United States. Patients having thyroid cancer that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have disease that was not controlled by previous treatment with radioactive iodine (131I) or not be good candidates for such treatment. The purpose of the study is to test whether the angiogenesis inhibitor AG-013736 is an effective treatment for metastatic thyroid cancer as shown by the number of patients in the study who experience significant and durable tumor shrinkage.
Key facts
- Study ID
- NCT00094055
- Run by
- Pfizer
- People needed
- 60
- Starts
- 2004-09-01
- Expected to finish
- 2009-01-01
- Last updated by the study team
- 2012-06-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically documented thyroid cancer with metastases.
- Failure of radioactive iodine (131I) to control the disease or radioactive iodine (131I) is not an appropriate therapy (e.g. due to lack of iodine uptake by the tumor)
You may not qualify if…
- Central lung lesions involving major blood vessels (arteries or veins).(Central lesions that maintain the structural integrity of vessels have the potential to bleed if the tumor lesion undergoes necrosis. MRI or CT angiography should be used in any case where there is any question as to whether blood vessels are involved.)
- Patients with a history of hemoptysis
Where it is running
- Pfizer Investigational Site — Santa Monica, California, United States
- Pfizer Investigational Site — Aurora, Colorado, United States
- Pfizer Investigational Site — Denver, Colorado, United States
- Pfizer Investigational Site — Chicago, Illinois, United States
- Pfizer Investigational Site — Baltimore, Maryland, United States
- Pfizer Investigational Site — Baltimore, Maryland, United States
- Pfizer Investigational Site — Ann Arbor, Michigan, United States
- Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
- Pfizer Investigational Site — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.